Profiles of Four New Stock-Billionaires
Oscotec shares rebound on launch of US clinical trial
Oscotec`s acute leukemia treatment wins orphan drug status from FDA
Oscotec wins exception policy for continued R&D for new drugs
Yuhan to start phase-3 trial on lung cancer drug Lazertinib
Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug
Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models
Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018
"ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC"
Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech
Other news to note for March 2, 2021
Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations